ACE inhibitor cilazapril: its place in cardiovascular diseases treatment
Abstract
ACE inhibitors play an important role in treatment of arterial hypertension, chronic heart failure, as well as in prevention of stroke and coronary heart disease complications. A new ACE inhibitor, cylasapril, is characterized by high antihypertensive efficacy and good tolerability. Cilasapril demonstrates cardio-, angio-, and nephroprotective effects. In patients with Type 2 diabetes mellitus and chronic renal insufficiency, cilasapril controls blood pressure, decreases proteinuria, and increases creatinine clearance. High cilasapril efficacy was proved in a Russian multicenter clinical trial, Initiative Program.
About the Author
G. A. Baryshnikova
Educational and Research Medical Center, Administration of the Russian Federation’s President Affairs, Moscow
Russian Federation
Russian Federation
References
1. Johnston CI, Cubela R, Jackson B. Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat. Clin Exp Pharmacol Physiol 1988; 15(2): 123-9.
2. Fabris B, Chen B, Pupic V, et al. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990; 15(Suppl 2): S6-13.
3. Kogler P. Cilazapril: a new non-thiol-containing angiotensinconverting enzyme inhibitor. Worldwide clinical experience in hypertension. Am J Med 1989; 87(6B): S 50-5.
4. Rosenthal JB, Osowski U. Tolerance and efficacy of antihypertensive therapy by cilazapril in common practice. Cardiology 1996; S7: 54-9.
5. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995; 8(3): 229-36.
6. Shieh SM, Sheu WH, Shen DD, et al. Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 1992; 5(8): 506-10.
7. Беленков Ю.Н., Агеев Ф.Т. Возможен ли адекватный контроль артериальной гипертонии в повседневной амбулаторной практике? Результаты Российского многоцентрового проекта «Инициатива». Справ поликлин врача 2004; 4: 3-8.
8. Kobrin I, Ben-Ishay D, Bompani R. Efficacy and safety of cilazapril in elderly patients with essential hypertension. Am J Med 1989; 88(Suppl 6B): S 33-6.
9. Dossegger L, Nielsen T, Preston C, Arabatzis N. Heart failure therapy with cilazapril: an overview. J Cardiovasc Pharmacol 1994; 24(Suppl 3): S38-41.
10. The Cilazapril-Captopril Multicenter Group. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. Cardiology 1995; 86(1): 34-40.
11. Bursztyn M, Kobrin I, Fidel J, Ben-Ishay D. Improved kidney function with cilazapril in hypertensive type II diabetics with chronic renal failure. J Cardiovasc Pharmacol 1991; 18(3): 337-41.
12. Schneeweiss A. Therapy conversion to cilazapril in angiotensin conversion enzyme inhibitor-induced cough. Evaluation of the effect. Cardiology 1993; 82(Suppl 2): 22-8.
13. Ольбинская Л.И., Белов А.А., Юсупова А.О. Клинические, кардиогемодинамические и респираторные эффекты ингибитора ангиотензин-превращающего фермента цилазаприла у больных артериальной гипертонией в сочетании с хронической обструктивной болезнью легких. Кардиоваск тер профил 2005; 4(1): 78-92.
Review
For citations:
Baryshnikova G.A. ACE inhibitor cilazapril: its place in cardiovascular diseases treatment. Cardiovascular Therapy and Prevention. 2005;4(4):116-120. (In Russ.)
Views:
476
Email this article 
